Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
Saved in:
| Title: | Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer. |
|---|---|
| Authors: | Li, Guiling1 (AUTHOR), Li, Xiaofan1,2 (AUTHOR), Yin, Rutie3 (AUTHOR), Feng, Mei4 (AUTHOR), Zuo, Jing5 (AUTHOR), Wei, Shuqing6 (AUTHOR), Kang, Shan7 (AUTHOR), Sun, Hongmei8 (AUTHOR), Li, Xiumin9 (AUTHOR), Wang, Yili10 (AUTHOR), Zhang, Yunyan11 (AUTHOR), Sun, Li12 (AUTHOR), Lin, Daren13 (AUTHOR), Ruan, Xiaohong13 (AUTHOR), Zhu, Zhitu14 (AUTHOR), Jiang, Kui15 (AUTHOR), Liu, Hu16 (AUTHOR), Wang, Wei17 (AUTHOR), Hao, Deshun18 (AUTHOR), Chen, Ying18 (AUTHOR) |
| Source: | Gynecologic Oncology. Dec2024, Vol. 191, p165-171. 7p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
